1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Analysis & Statistics 2020 - European Union

Cancer Analysis & Statistics 2020 - European Union

Customer Support

Talk to Ahmad

+1 718 618 4302

All regions

data types

1-19 of 19 reports

Avastin

  • $ 10000
  • March 2019
  • 111 pages

Avastin (bevacizumab; Genentech/Roche/Chugai) is a humanized immunoglobulin G1 monoclonal antibody directed against vascular endothelial growth factor (VEGF).

  • Cancer
  • Pathology
  • European Union
  • Japan
  • United States

Alimta

  • $ 10000
  • August 2018
  • 27 pages

Drug Overview Alimta (pemetrexed; Eli Lilly) is an antifolate antineoplastic agent that exerts its action by disrupting folate-dependent metabolic processes essential for cell replication. Similar to fluorouracil, ...

  • Cancer
  • European Union
  • Japan
  • United States
  • Litigation And Patent

Abraxane

  • $ 10000
  • August 2018
  • 48 pages

Drug Overview Abraxane (nab-paclitaxel; Celgene/Taiho) is an albumin-bound formulation of paclitaxel, an antimicrotubule taxane that interferes with the growth of tumors by inhibiting mitosis during metaphase. ...

  • Cancer
  • Pathology
  • European Union
  • Japan
  • United States

Gilotrif

  • $ 10000
  • August 2018
  • 37 pages

Drug Overview Gilotrif (afatinib; Boehringer Ingelheim) is an orally administered tyrosine kinase inhibitor (TKI) that irreversibly binds to epidermal growth factor receptor (EGFR)/human epidermal growth ...

  • Cancer
  • Lung Cancer
  • European Union
  • Japan
  • United States

Dacomitinib

  • $ 10000
  • August 2018
  • 18 pages

Drug Overview Dacomitinib is a small-molecule, irreversible inhibitor of HER1, HER2, and HER4, under development by Pfizer. Mutation or amplification of the HER gene is seen in several malignancies including ...

  • Cancer
  • Lung Cancer
  • Pathology
  • European Union
  • Japan

Velcade

  • $ 10000
  • August 2018
  • 31 pages

Drug Overview Velcade (bortezomib; Takeda/Johnson and Johnson) is an intravenously or subcutaneously administered 26S proteasome inhibitor that affects multiple signaling cascades and induces cell death. ...

  • Cancer
  • Lymphoma
  • Pathology
  • Therapy
  • European Union

Kyprolis

  • $ 10000
  • August 2018
  • 36 pages

Drug Overview Kyprolis (carfilzomib; Amgen/Ono Pharmaceutical) is a second-generation proteasome inhibitor that irreversibly binds to the N-terminal threonine-containing active sites of the 20S proteasome, ...

  • Cancer
  • Pathology
  • European Union
  • Japan
  • United States

Darzalex

  • $ 10000
  • August 2018
  • 37 pages

Drug Overview Darzalex (daratumumab; Johnson and Johnson) targets the transmembrane glycoprotein CD38, which is highly expressed on malignant multiple myeloma cells, but expressed at low levels in othe ...

  • Cancer
  • Pathology
  • European Union
  • Japan
  • Product Initiative

Drug Overview: Tecentriq

  • $ 10000
  • January 2018
  • 82 pages

Drug Overview Tecentriq (atezolizumab; Roche/Chugai) is a fully humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1). PD-L1 is expressed on the surface of antigen-presenting cells ...

  • Cancer
  • Colorectal Cancer
  • Pathology
  • European Union
  • United States

Drug Analysis: Tecentriq

  • $ 10000
  • January 2018
  • 82 pages

Drug Overview Tecentriq (atezolizumab; Roche/Chugai) is a fully humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1). PD-L1 is expressed on the surface of antigen-presenting cells ...

  • Cancer
  • Colorectal Cancer
  • Pathology
  • European Union
  • United States

Drug analysis: Opdivo

  • $ 10000
  • December 2017
  • 103 pages

Drug Overview Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) is a fully human immunoglobulin G4 programmed death-1 (PD-1) immune checkpoint inhibitor that binds to the checkpoint recepto ...

  • Cancer
  • Pathology
  • European Union
  • United States

Drug analysis: Avastin

  • $ 10000
  • December 2017
  • 116 pages

Drug Overview Avastin (bevacizumab; Genentech/Roche/Chugai) is a humanized immunoglobulin G1 monoclonal antibody directed against vascular endothelial growth factor (VEGF). The VEGF protein is an essential ...

  • Breast Cancer
  • Cancer
  • Pathology
  • European Union
  • Product Initiative

Drug analysis: Keytruda

  • $ 10000
  • December 2017
  • 120 pages

Drug Overview Keytruda (pembrolizumab; Merck and Co) is a humanized monoclonal antibody designed to inhibit the programmed death-1 (PD-1) co-inhibitory receptor. The interaction between PD-1 and its primary ...

  • Cancer
  • Pathology
  • European Union
  • Japan
  • United States

Drug Analysis: Gilotrif

  • $ 10000
  • December 2017
  • 31 pages

Drug Overview Gilotrif is an orally administered TKI that irreversibly binds to EGFR/human epidermal growth factor receptor 1 (HER1), HER2, and HER4. In cancerous cells where EGFR and HER2 receptors are ...

  • Cancer
  • Lung Cancer
  • European Union
  • Japan
  • United States

Drug Analysis: Imfinzi

  • $ 10000
  • December 2017
  • 41 pages

Drug Overview AstraZeneca’s Imfinzi is a human monoclonal antibody targeting PD-L1. Programmed death-1 (PD-1) and its ligands, PD-L1 and PD-L2, are members of the cluster of differentiation (CD)28 and ...

  • Bladder Cancer
  • Cancer
  • Lung Cancer
  • Pathology
  • European Union

Drug Analysis: Bavencio

  • $ 10000
  • December 2017
  • 64 pages

Drug Overview Bavencio is a fully human MAb targeting the PD-L1 protein. The interaction between PD-L1 and its receptor, programmed death-1 (PD-1), regulates complex signaling pathways that affect T-cell ...

  • Cancer
  • Lung Cancer
  • Pathology
  • European Union
  • Japan

Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) - Pipeline Review, H2 2016

  • $ 3500
  • November 2016
  • 69 pages

Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Thrombopoietin Receptor (Myeloproliferative ...

  • Cancer
  • Hospital
  • Therapy
  • European Union
  • Product Initiative

Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) - Pipeline Review, H1 2016

  • $ 3500
  • June 2016
  • 68 pages

Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Thrombopoietin Receptor (Myeloproliferative ...

  • Blood Disease
  • Cancer
  • Therapy
  • European Union
  • Product Initiative

Non-Small Cell Lung Cancer: Update Bulletin [Jan 2016]

  • $ 1077
  • January 2016
  • 1 pages

Gain new KOL insights on the latest events that have the potential to shape the targeted treatment of Non-Small Cell Lung Cancer (NSCLC). Topics covered include opinions about Tagrisso (osimertinib; AstraZeneca) ...

  • Cancer
  • Lung Cancer
  • Pathology
  • Therapy
  • European Union



Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on